Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.

Kehr EL, Jorns JM, Ang D, Warrick A, Neff T, Degnin M, Lewis R, Beadling C, Corless CL, Troxell ML.

Hum Pathol. 2012 Dec;43(12):2207-12. doi: 10.1016/j.humpath.2012.03.012. Epub 2012 Jun 15.

PMID:
22705004
2.

PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.

Flatley E, Ang D, Warrick A, Beadling C, Corless CL, Troxell ML.

Hum Pathol. 2013 Jul;44(7):1320-7. doi: 10.1016/j.humpath.2012.10.018. Epub 2013 Jan 24.

PMID:
23352210
3.

High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.

Troxell ML, Levine J, Beadling C, Warrick A, Dunlap J, Presnell A, Patterson J, Shukla A, Olson NR, Heinrich MC, Corless CL.

Mod Pathol. 2010 Jan;23(1):27-37. doi: 10.1038/modpathol.2009.142. Epub 2009 Nov 6.

4.

Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.

Troxell ML, Brunner AL, Neff T, Warrick A, Beadling C, Montgomery K, Zhu S, Corless CL, West RB.

Mod Pathol. 2012 Jul;25(7):930-7. doi: 10.1038/modpathol.2012.55. Epub 2012 Mar 30.

5.

Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.

Ang DC, Warrick AL, Shilling A, Beadling C, Corless CL, Troxell ML.

Mod Pathol. 2014 May;27(5):740-50. doi: 10.1038/modpathol.2013.197. Epub 2013 Nov 1.

6.

Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.

Dunlap J, Le C, Shukla A, Patterson J, Presnell A, Heinrich MC, Corless CL, Troxell ML.

Breast Cancer Res Treat. 2010 Apr;120(2):409-18. doi: 10.1007/s10549-009-0406-1. Epub 2009 May 6.

PMID:
19418217
7.

PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.

Li H, Zhu R, Wang L, Zhu T, Li Q, Chen Q, Wang H, Zhu H.

Exp Mol Pathol. 2010 Feb;88(1):150-5. doi: 10.1016/j.yexmp.2009.09.016. Epub 2009 Oct 8.

PMID:
19818761
8.

[PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].

Li SY, Wang W, Li JM, Wang Z, Wen RY, Chen J, Miao XT.

Zhonghua Zhong Liu Za Zhi. 2011 Aug;33(8):605-8. Chinese.

PMID:
22325221
9.

PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.

Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, Salvatore S, Cuccurullo F, Mezzetti A, Campani D, Marchetti A.

J Pathol. 2006 Feb;208(3):350-5.

PMID:
16353168
10.

PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.

Kalinsky K, Heguy A, Bhanot UK, Patil S, Moynahan ME.

Breast Cancer Res Treat. 2011 Sep;129(2):635-43. doi: 10.1007/s10549-011-1601-4. Epub 2011 May 27.

PMID:
21617917
11.

Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.

Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):408-14. Epub 2007 Jan 3.

12.

Mammary mucinous lesions: congeners, prevalence and important pathological associations.

Chinyama CN, Davies JD.

Histopathology. 1996 Dec;29(6):533-9.

PMID:
8971560
13.

Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type.

Lacroix-Triki M, Suarez PH, MacKay A, Lambros MB, Natrajan R, Savage K, Geyer FC, Weigelt B, Ashworth A, Reis-Filho JS.

J Pathol. 2010 Nov;222(3):282-98. doi: 10.1002/path.2763.

PMID:
20815046
14.

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.

BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.

15.

Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.

Deng L, Chen J, Zhong XR, Luo T, Wang YP, Huang HF, Yin LJ, Qiu Y, Bu H, Lv Q, Zheng H.

PLoS One. 2015 Mar 27;10(3):e0120511. doi: 10.1371/journal.pone.0120511. eCollection 2015.

16.

Correlation of breast cancer axillary lymph node metastases with stem cell mutations.

Donovan CA, Pommier RF, Schillace R, O'Neill S, Muller P, Alabran JL, Hansen JE, Murphy JA, Naik AM, Vetto JT, Pommier SJ.

JAMA Surg. 2013 Sep;148(9):873-8. doi: 10.1001/jamasurg.2013.3028.

PMID:
23884447
17.

Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.

Harlé A, Lion M, Lozano N, Husson M, Harter V, Genin P, Merlin JL.

Oncol Rep. 2013 Mar;29(3):1043-52. doi: 10.3892/or.2013.2229. Epub 2013 Jan 8.

PMID:
23314198
18.

PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases.

Michelucci A, Di Cristofano C, Lami A, Collecchi P, Caligo A, Decarli N, Leopizzi M, Aretini P, Bertacca G, Porta RP, Ricci S, Della Rocca C, Stanta G, Bevilacqua G, Cavazzana A.

Diagn Mol Pathol. 2009 Dec;18(4):200-5. doi: 10.1097/PDM.0b013e31818e5fa4.

PMID:
19861897
19.

p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.

Done SJ, Arneson NC, Ozçelik H, Redston M, Andrulis IL.

Cancer Res. 1998 Feb 15;58(4):785-9.

20.

Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.

Juanpere N, Agell L, Lorenzo M, de Muga S, López-Vilaró L, Murillo R, Mojal S, Serrano S, Lorente JA, Lloreta J, Hernández S.

Hum Pathol. 2012 Oct;43(10):1573-82. doi: 10.1016/j.humpath.2011.10.026. Epub 2012 Mar 12.

PMID:
22417847

Supplemental Content

Support Center